Supergenics Stock

SGBHD

MYL03033O007

Biotechnology & Medical Research

Market Closed - BURSA MALAYSIA Other stock markets 12:50:01 30/12/2025 +04			5-day change	1st Jan Change
0.2500 ^MYR	+21.95%		-.--%	-

04-30	Supergenics Berhad Auditor Raises 'Going Concern' Doubt	CI
02-27	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2025	CI

on all subscriptions*

Last days

Enjoy this offer

* See conditions under "Our services"

Supergenics Berhad is a Malaysia-based management and investment holding company. The Company operates through three segments: Integrated Turnkey Solutions, Biomedical, and Investment Holding. Its Integrated Turnkey Solutions segment is engaged in the provision of integrated turnkey solutions for the related development of cleanrooms and the provision of related maintenance services. Its Biomedical segment is engaged in the provision of administrative health care services, operating medical laboratories, and developing regenerative wellness products. The Company provides laboratory services, including storage and handling of stem cell samples. Its services include stem cells, mesenchymal stem cells (MSC), natural killer (NK) cells, exosomes, and MSC exosomes. Its subsidiaries include Supergenics Solution Sdn. Bhd., Supergenics Life Science Sdn. Bhd., Supergenics Therapeutic Sdn. Bhd., Supergenics Bio Agro Sdn. Bhd., Supergenics Stembank Sdn. Bhd., and Supergenics Global Sdn. Bhd.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Stock Market
Stocks
SGBHD Stock

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrows Top Investments!

SEIZE THE OFFER!

Market Cap	29.11M 7.17M 6.2M 5.71M 5.34M 10.02M 682M 10.17M 67.42M 26.29M 332M 26.92M 26.35M 1.15B	P/E Ratio 2024	-9.45x	P/E Ratio 2025	-8.61x
Enterprise Value	32.5M 8.01M 6.92M 6.38M 5.97M 11.18M 761M 11.36M 75.28M 29.35M 371M 30.06M 29.42M 1.28B	EV / Sales 2024	13.9x	EV / Sales 2025	5.78x
Free-Float	41.6%	Yield 2024 *	-	Yield 2025	-

04-30	Supergenics Berhad Auditor Raises 'Going Concern' Doubt	CI
02-27	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-05	Supergenics Seeks 6-Month Extension to Complete Private Placement of Shares	MT
29/08/25	Supergenics Berhad Reports Earnings Results for the Half Year Ended June 30, 2025	CI
27/08/25	Supergenics fixes issue price at 0.27 RGT per share	RE
12/08/25	Supergenics Berhad Announces the Redesignation of Lau Meng Hong from Executive Director to Non Independent and Non Executive Director, Effective August 12, 2025	CI
21/03/25	Supergenics Berhad Announces Change of Registered Office Address	CI
28/02/25	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2024	CI
30/08/24	Supergenics Berhad Reports Earnings Results for the Half Year Ended June 30, 2024	CI
02/04/24	Supergenics Seeks More Time to Complete Private Share Placement	MT
29/02/24	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2023	CI
29/02/24	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2023	CI
06/01/24	41,850,000 Ordinary Shares of Supergenics Berhad are subject to a Lock-Up Agreement Ending on 6-JAN-2024.	CI

1 year	0.2	0.25
3 years	0.15	0.6
5 years	0.15	0.6
10 years	0.15	0.6

Manager	Title	Age	Since
Bii Chau Tan CEO	Chief Executive Officer	48	24/04/2019
Yuet Chyn Wong SEC	Corporate Secretary	-	02/06/2022

Director	Title	Age	Since
Fun Kim Ng BRD	Director/Board Member	60	24/04/2019
Bii Chau Tan BRD	Director/Board Member	48	24/04/2019
Kiat Yang Chan BRD	Director/Board Member	46	28/01/2022

Supergenics Stock

Stocks

SGBHD

MYL03033O007

Biotechnology & Medical Research

Valuation: Supergenics

Chart: Supergenics

Latest news : Supergenics

Quotes and Performance

Course Extremes

Managers and Directors: Supergenics

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SUPERGENICS	+21.95%	-.--%	-16.67%	-15.25%	7.17M
LONZA GROUP AG	-0.35%	+0.97%	-13.80%	-13.25%	43.03B
REVOLUTION MEDICINES, INC.	+3.11%	+3.11%	+279.08%	+501.52%	32.71B
IQVIA HOLDINGS INC.	+0.22%	-1.08%	+15.66%	-15.65%	30.29B
BEONE MEDICINES AG	+1.62%	-2.08%	-1.91%	+24.64%	29.4B
CELLTRION, INC.	+4.09%	+0.93%	+12.97%	+20.22%	25.08B
ASCENDIS PHARMA A/S	+1.14%	+3.62%	-	-	13.54B
MEDPACE HOLDINGS, INC.	-1.63%	+2.88%	+56.69%	+113.41%	13.35B
EUROFINS SCIENTIFIC SE	-0.40%	-1.29%	+6.23%	+7.63%	12.97B
IONIS PHARMACEUTICALS, INC.	-0.74%	-1.62%	+105.89%	+74.92%	12.11B
Average	+2.90%	+1.30%	+49.35%	+77.58%	21.25B
Weighted average by Cap.	+1.05%	+1.48%	+57.30%	+96.08%

	2024	2025
Net sales	5.32M 1.31M 1.13M 1.04M 977K 1.83M 125M 1.86M 12.33M 4.81M 60.68M 4.92M 4.82M 210M	5.63M 1.39M 1.2M 1.1M 1.03M 1.94M 132M 1.97M 13.03M 5.08M 64.14M 5.2M 5.09M 222M
Net income	-7.28M -1.79M -1.55M -1.43M -1.34M -2.51M -171M -2.54M -16.86M -6.57M -83.02M -6.73M -6.59M -287M	-3.37M -829K -716K -660K -618K -1.16M -78.84M -1.18M -7.8M -3.04M -38.38M -3.11M -3.05M -133M
Net Debt	4.48M 1.1M 953K 878K 822K 1.54M 105M 1.56M 10.37M 4.04M 51.05M 4.14M 4.05M 177M	3.39M 836K 722K 666K 623K 1.17M 79.51M 1.19M 7.86M 3.06M 38.7M 3.14M 3.07M 134M

1 day	+21.95%
6 months	+21.95%